{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:07:46Z","timestamp":1781262466644,"version":"3.54.1"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Vaccination plays a critical role in mitigating the burden associated with yellow fever (YF). However, there is a lack of comprehensive evidence on the humoral response to primary vaccination in the paediatric population, with several questions debated, including the response when the vaccine is administered at early ages, the effect of co-administration with other vaccines, the duration of immunity and the use of fractional doses, among others. This study summarizes the existing evidence regarding the humoral response to primary YF vaccination in infants and children.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Studies on the humoral response to primary YF vaccination in children aged 12\u00a0years or younger were reviewed. The humoral vaccine response rate (VRR), i.e. the proportion of children who tested positive for vaccine-induced YF-specific neutralizing antibodies, was pooled through random-effects meta-analysis and categorized based on the time elapsed since vaccination. Subgroup, meta-regression and sensitivity analyses were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 33 articles met the inclusion criteria, with all but one conducted in countries where YF is endemic. A total of 14\u2009028 infants and children entered this systematic review. Within three months following vaccination, the pooled VRR was 91.9% (95% CI 89.8\u201393.9). A lower VRR was observed with the 17DD vaccine at the meta-regression analysis. No significant differences in immunogenicity outcomes were observed based on age, administration route, co-administration with other vaccines, or fractional dosing. Results also indicate a decline in VRR over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Primary YF vaccination effectively provides humoral immunity in paediatric population. However, humoral response declines over time, and this decline is observable after the first 18\u00a0months following vaccination. A differential response according to the vaccine substrain was also observed. This research has valuable implications for stimulating further research on the primary YF vaccination in infants and children, as well as for informing future policies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taae039","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T01:24:58Z","timestamp":1709601898000},"source":"Crossref","is-referenced-by-count":3,"title":["Humoral immunogenicity of primary yellow fever vaccination in infants and children: a systematic review, meta-analysis and meta-regression"],"prefix":"10.1093","volume":"31","author":[{"given":"Pietro","family":"Ferrara","sequence":"first","affiliation":[{"name":"Center for Public Health Research (CESP), University of Milan-Bicocca , Monza , Italy"},{"name":"Laboratory of Public Health, IRCCS Istituto Auxologico Italiano , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Losa","sequence":"additional","affiliation":[{"name":"Center for Public Health Research (CESP), University of Milan-Bicocca , Monza , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo G","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Center for Public Health Research (CESP), University of Milan-Bicocca , Monza , Italy"},{"name":"Laboratory of Public Health, IRCCS Istituto Auxologico Italiano , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[{"name":"Infectious Disease Department , School of Medicine, , Barcelona , Spain"},{"name":"University of Barcelona , School of Medicine, , Barcelona , Spain"},{"name":"HIV Unit , Infectious Diseases Service, , Barcelona , Spain"},{"name":"Hospital Clinic\u2014Fundaci\u00f3 de Recerca Cl\u00ednic Barcelon\u2014IDIBAPS , Infectious Diseases Service, , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Ag\u00fcero","sequence":"additional","affiliation":[{"name":"Unit of Preventive Medicine, Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"2024040613410979800_ref1","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/B978-0-323-79058-1.00064-5","volume-title":"Plotkin\u2019s Vaccines","author":"Staples","year":"2023"},{"key":"2024040613410979800_ref2","volume-title":"Recommendations to Assure the Quality, Safety and Efficacy of Live Attenuated Yellow Fever Vaccines, Annex 5, TRS No 978","author":"World Health Organization","year":"2013"},{"key":"2024040613410979800_ref3","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/14760584.2016.1198259","article-title":"Questions regarding the safety and duration of immunity following live yellow fever vaccination","volume":"15","author":"Amanna","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2024040613410979800_ref4","volume-title":"Countries with Risk of Yellow Fever Transmission and Countries Requiring Yellow Fever Vaccination (November 2022)","author":"World Health Organization","year":"2022"},{"key":"2024040613410979800_ref5","volume-title":"Yellow Fever Vaccine Recommendations","author":"US Centers for Disease Control and Prevention","year":"2021"},{"key":"2024040613410979800_ref6","volume-title":"Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Yellow Fever Vaccine Booster Doses","author":"US Centers for Disease Control and Prevention","year":"2015"},{"key":"2024040613410979800_ref7","doi-asserted-by":"crossref","first-page":"6954","DOI":"10.1016\/j.vaccine.2020.08.042","article-title":"Yellow fever in children and adolescents previously immunized in Minas Gerais state, Brazil","volume":"38","author":"Diniz","year":"2020","journal-title":"Vaccine"},{"key":"2024040613410979800_ref8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-020-0205-6","article-title":"Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection","volume":"5","author":"Staples","year":"2020","journal-title":"Npj Vaccines"},{"key":"2024040613410979800_ref9","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S1473-3099(20)30170-5","article-title":"Prevention of yellow fever in travellers: an update","volume":"20","author":"Reno","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2024040613410979800_ref10","volume-title":"Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook","author":"US Centers for Disease Control and Prevention","year":"2021","edition":"14th"},{"key":"2024040613410979800_ref11","volume-title":"Fractional Dose Yellow Fever Vaccine as a Dose-Sparing Option for Outbreak Response: WHO Secretariat Information Paper","author":"World Health Organization","year":"2016"},{"key":"2024040613410979800_ref12","first-page":"647","article-title":"Yellow fever vaccine booster doses: recommendations of the advisory committee on immunization practices, 2015","volume":"64","author":"Staples","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024040613410979800_ref13","doi-asserted-by":"crossref","first-page":"113568","DOI":"10.1016\/j.jim.2023.113568","article-title":"Standardization, validation, and comparative evaluation of a faster and high-performance test for quantification of yellow fever neutralizing antibodies","volume":"522","author":"Sim\u00f5es","year":"2023","journal-title":"J Immunol Methods"},{"key":"2024040613410979800_ref14","volume-title":"Laboratory diagnosis of yellow fever virus infection","author":"Pan American Health Organization","year":"():"},{"key":"2024040613410979800_ref15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tvjl.2012.08.019","article-title":"Review of diagnostic plaque reduction neutralization tests for flavivirus infection","volume":"195","author":"Maeda","year":"2013","journal-title":"Vet J"},{"key":"2024040613410979800_ref16","volume-title":"Humoral immunogenicity of primary yellow fever vaccination in infants and children: a systematic review and meta-analysis (CRD42022334498)","author":"PROSPERO"},{"key":"2024040613410979800_ref17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024040613410979800_ref18","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.vaccine.2023.02.007","article-title":"Factors associated with yellow fever vaccine failure: a systematic literature review","volume":"41","author":"Fantinato","year":"2023","journal-title":"Vaccine"},{"key":"2024040613410979800_ref19","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/cid\/ciac580","article-title":"Duration of protection after vaccination against yellow fever: a systematic review and meta-analysis","volume":"75","author":"Kling","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024040613410979800_ref20","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.vaccine.2019.12.018","article-title":"Immunogenicity and safety of fractional dose yellow fever vaccination: a systematic review and meta-analysis","volume":"38","author":"Nnaji","year":"2020","journal-title":"Vaccine"},{"key":"2024040613410979800_ref21","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.16-0401","article-title":"A meta-analysis of serological response associated with yellow fever vaccination","volume":"95","author":"Jean","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2024040613410979800_ref22","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024040613410979800_ref23","volume-title":"Critical appraisal tools for use in JBI systematic reviews: checklist for non-randomized experimental studies","author":"Joanna Briggs Institute"},{"key":"2024040613410979800_ref24","volume-title":"How to Conduct a Meta-Analysis of Proportions in R: A Comprehensive Tutorial","author":"Wang","year":"2018"},{"key":"2024040613410979800_ref25","volume-title":"Doing Meta-Analysis with R: A Hands-on Guide","author":"Harrer","year":"2022","edition":"First"},{"key":"2024040613410979800_ref26","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-Analysis with R","author":"Schwarzer","year":"2015"},{"key":"2024040613410979800_ref27","author":"R Foundation for Statistical Computing"},{"key":"2024040613410979800_ref28","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4.","author":"Deeks","year":"2023"},{"key":"2024040613410979800_ref29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2024040613410979800_ref30","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S1473-3099(23)00131-7","article-title":"Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial","volume":"23","author":"Juan-Giner","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024040613410979800_ref31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12879-023-08114-1","article-title":"Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina","volume":"23","author":"Vizzotti","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2024040613410979800_ref32","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.vaccine.2021.12.029","article-title":"Exploratory study of humoral and cellular immunity to 17DD yellow fever vaccination in children and adults residents of areas without circulation of yellow fever virus","volume":"40","author":"Reis","year":"2022","journal-title":"Vaccine"},{"key":"2024040613410979800_ref33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijid.2021.05.061","article-title":"Safety and immunogenicity of vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial","volume":"108","author":"Sirima","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2024040613410979800_ref34","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1016\/j.vaccine.2020.03.014","article-title":"Immunogenicity and safety of the RTS,S\/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: a phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial","volume":"38","author":"Asante","year":"2020","journal-title":"Vaccine"},{"key":"2024040613410979800_ref35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577751","article-title":"Serological protection 5\u20136 years post vaccination against yellow fever in African infants vaccinated in routine programmes","volume":"11","author":"Idoko","year":"2020","journal-title":"Front Immunol"},{"key":"2024040613410979800_ref36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJMoa1710430","article-title":"Immunogenicity of fractional-dose vaccine during a yellow fever outbreak \u2014 final report","volume":"381","author":"Casey","year":"2019","journal-title":"N Engl J Med"},{"key":"2024040613410979800_ref37","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1016\/j.vaccine.2019.09.051","article-title":"Duration of post-vaccination humoral immunity against yellow fever in children","volume":"37","author":"Noronha","year":"2019","journal-title":"Vaccine"},{"key":"2024040613410979800_ref38","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S1473-3099(19)30323-8","article-title":"Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study","volume":"19","author":"Domingo","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024040613410979800_ref39","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/infdis\/jiy215","article-title":"Evaluation of a booster dose of pentavalent rotavirus vaccine Coadministered with measles, yellow fever, and meningitis a vaccines in 9-month-old Malian infants","volume":"218","author":"Haidara","year":"2018","journal-title":"J Infect Dis"},{"key":"2024040613410979800_ref40","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.1016\/j.vaccine.2017.09.047","article-title":"CHRONOVAC VOYAGEUR: a study of the immune response to yellow fever vaccine among infants previously immunized against measles","volume":"35","author":"Goujon","year":"2017","journal-title":"Vaccine"},{"key":"2024040613410979800_ref41","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2214-109X(16)30075-4","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine when given with measles\u2013rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in the Gambia","volume":"4","author":"Clarke","year":"2016","journal-title":"Lancet Glob Health"},{"key":"2024040613410979800_ref42","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/INF.0000000000001250","article-title":"Immunogenicity and safety of yellow fever vaccine (Stamaril) when administered concomitantly with a tetravalent dengue vaccine candidate in healthy toddlers at 12\u201313 months of age in Colombia and Peru: a randomized trial","volume":"35","author":"L\u00f3pez","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2024040613410979800_ref43","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1590\/0074-02760150176","article-title":"A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213\/77 in children nine-23 months old","volume":"110","author":"Collaborative Group for Studies of Yellow Fever Vaccine","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2024040613410979800_ref44","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1093\/cid\/civ603","article-title":"Immunogenicity of yellow fever vaccine coadministered with MenAfriVac in healthy infants in Ghana and Mali","volume":"61","author":"Roy Chowdhury","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024040613410979800_ref45","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.vaccine.2015.03.069","article-title":"Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?","volume":"33","author":"Michel","year":"2015","journal-title":"Vaccine"},{"key":"2024040613410979800_ref46","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/infdis\/jir439","article-title":"Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody","volume":"204","author":"Luiza-Silva","year":"2011","journal-title":"J Infect Dis"},{"key":"2024040613410979800_ref47","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1016\/j.vaccine.2011.05.019","article-title":"Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella","volume":"29","author":"Nascimento Silva","year":"2011","journal-title":"Vaccine"},{"key":"2024040613410979800_ref48","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/656190","article-title":"Evaluation of the safety and immunogenicity of the RTS,S\/AS01 E malaria candidate vaccine when integrated in the expanded program of immunization","volume":"202","author":"Agnandji","year":"2010","journal-title":"J Infect Dis"},{"key":"2024040613410979800_ref49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru","volume":"72","author":"Belmusto-Worn","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"2024040613410979800_ref50","first-page":"1056","article-title":"Antibody response to 17D yellow fever vaccine in Ghanaian infants","volume":"79","author":"Osei-Kwasi","year":"2001","journal-title":"Bull World Health Organ"},{"key":"2024040613410979800_ref51","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0264-410X(98)00320-X","article-title":"Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine","volume":"17","author":"Stefano","year":"1999","journal-title":"Vaccine"},{"key":"2024040613410979800_ref52","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/00006454-199712000-00015","article-title":"Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1","volume":"16","author":"Sibailly","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"2024040613410979800_ref53","first-page":"579","article-title":"Field trial of combined yellow fever and measles vaccines among children in Nigeria","volume":"73","author":"Adu","year":"1996","journal-title":"East Afr Med J"},{"key":"2024040613410979800_ref54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0264-410X(95)80020-E","article-title":"Simultaneous injection of plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines","volume":"13","author":"Coursaget","year":"1995","journal-title":"Vaccine"},{"key":"2024040613410979800_ref55","first-page":"885","article-title":"a new combined vaccine against yellow fever and measles in infants aged 6 to 24 months in Mali","volume":"84","author":"Soula","year":"1991","journal-title":"Bull Soc Pathol Exot 1990"},{"key":"2024040613410979800_ref56","first-page":"537","article-title":"the combined measles-yellow fever vaccination in African infants aged 6 to 10 months","volume":"83","author":"Mouchon","year":"1990","journal-title":"Bull Soc Pathol Exot 1990"},{"key":"2024040613410979800_ref57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0092-1157(89)90023-1","article-title":"Study of combined vaccination against yellow fever and measles in infants from six to nine months","volume":"17","author":"Lhuillier","year":"1989","journal-title":"J Biol Stand"},{"key":"2024040613410979800_ref58","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jmv.1890190403","article-title":"Simultaneous administration of hepatitis B and yellow fever vaccines","volume":"19","author":"Yvonnet","year":"1986","journal-title":"J Med Virol"},{"key":"2024040613410979800_ref59","first-page":"536","article-title":"use of stabilized yellow fever vaccine 17D at the time of the yellow fever epidemic in Burkina Faso in 1983","volume":"78","author":"Saluzzo","year":"1985","journal-title":"Bull Soc Pathol Exot Filiales"},{"key":"2024040613410979800_ref60","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0264-410X(85)90182-3","article-title":"Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine","volume":"3","author":"Georges","year":"1985","journal-title":"Vaccine"},{"key":"2024040613410979800_ref61","first-page":"387","article-title":"study of a new pentavalent vaccine combination","volume":"124","author":"Gateff","year":"1973","journal-title":"Ann Microbiol (Paris)"},{"key":"2024040613410979800_ref62","first-page":"175","article-title":"Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to Nigerian children","volume":"48","author":"Ruben","year":"1973","journal-title":"Bull World Health Organ"},{"key":"2024040613410979800_ref63","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/vaccines9060671","article-title":"What constitutes protective immunity following yellow fever vaccination?","volume":"9","author":"Mokaya","year":"2021","journal-title":"Vaccine"},{"key":"2024040613410979800_ref64","doi-asserted-by":"crossref","first-page":"taab126","DOI":"10.1093\/jtm\/taab126","article-title":"Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: a 10-year follow-up study","volume":"28","author":"Rosenstein","year":"2021","journal-title":"J Travel Med"},{"key":"2024040613410979800_ref65","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2214-109X(23)00556-9","article-title":"Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis","volume":"12","author":"Schnyder","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2024040613410979800_ref66","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14760584.2019.1640118","article-title":"Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children","volume":"18","author":"Idoko","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"2024040613410979800_ref67","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/erv.10.41","article-title":"The challenge of assessing infant vaccine responses in resource-poor settings","volume":"9","author":"Flanagan","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"2024040613410979800_ref68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/B978-0-323-79058-1.00002-5","volume-title":"Plotkin\u2019s Vaccines","author":"Siegrist","year":"2023"},{"key":"2024040613410979800_ref69","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Marchesani","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"2024040613410979800_ref70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/14760584.2018.1406800","article-title":"The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences","volume":"17","author":"Ferreira","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"2024040613410979800_ref71","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.chom.2021.12.009","article-title":"Genotype-specific features reduce the susceptibility of south American yellow fever virus strains to vaccine-induced antibodies","volume":"30","author":"Haslwanter","year":"2022","journal-title":"Cell Host Microbe"},{"key":"2024040613410979800_ref72","article-title":"Immunological factors linked to geographical variation in vaccine responses","author":"Van Dorst","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2024040613410979800_ref73","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1172\/JCI75429","article-title":"Immune activation alters cellular and humoral responses to yellow fever 17D vaccine","volume":"124","author":"Muyanja","year":"2014","journal-title":"J Clin Invest"},{"key":"2024040613410979800_ref74","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(20)32520-4","article-title":"Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial","volume":"397","author":"Juan-Giner","year":"2021","journal-title":"The Lancet"},{"key":"2024040613410979800_ref75","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/infdis\/jiz375","article-title":"Global risk and elimination of yellow fever epidemics","volume":"221","author":"Ndeffo-Mbah","year":"2020","journal-title":"J Infect Dis"},{"key":"2024040613410979800_ref76","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1473-3099(23)00205-0","article-title":"Fractional dose yellow fever vaccination, coming of age","volume":"23","author":"Roukens","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024040613410979800_ref77","volume-title":"Disease Outbreak News; Yellow Fever in East, West, and Central Africa","author":"World Health Organization","year":"2022"},{"key":"2024040613410979800_ref78","first-page":"S1473309923008095","article-title":"Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study","author":"Doshi","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2024040613410979800_ref79","first-page":"S1473309924000082","article-title":"Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines","author":"Juan-Giner","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2024040613410979800_ref80","doi-asserted-by":"crossref","first-page":"e02548","DOI":"10.1128\/spectrum.02548-21","article-title":"A high-throughput yellow fever neutralization assay","volume":"10","author":"Rasulova","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2024040613410979800_ref81","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"Julander","year":"2011","journal-title":"Vaccine"},{"key":"2024040613410979800_ref82","volume-title":"Lifetime Validity of One Dose of Yellow Fever Vaccine","author":"World Health Organization","year":"2014"},{"key":"2024040613410979800_ref83","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2024040613410979800_ref84","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3389\/fimmu.2019.02192","article-title":"Short-lived immunity after 17DD yellow fever single dose indicates that booster vaccination may be required to guarantee protective immunity in children","volume":"10","author":"Campi-Azevedo","year":"2019","journal-title":"Front Immunol"},{"key":"2024040613410979800_ref85","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S1473-3099(17)30419-X","article-title":"Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis","volume":"17","author":"Shearer","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2024040613410979800_ref86","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41598-017-00798-1","article-title":"Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination","volume":"7","author":"Kongsgaard","year":"2017","journal-title":"Sci Rep"},{"key":"2024040613410979800_ref87","first-page":"125","article-title":"Failure of antibody production to yellow fever vaccine in children with kwashiorkor","volume":"18","author":"Brown","year":"1966","journal-title":"Trop Geogr Med"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taae039\/57119156\/taae039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/31\/3\/taae039\/57174564\/taae039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/31\/3\/taae039\/57174564\/taae039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T13:41:46Z","timestamp":1712410906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taae039\/7619020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":87,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,4]]},"published-print":{"date-parts":[[2024,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taae039","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,3,4]]},"article-number":"taae039"}}